Teva, Boehringer Slapped With New Pay-For-Delay Suit

Law360, Los Angeles (January 24, 2014, 6:03 PM EST) -- Teva Pharmaceuticals Inc. and Boehringer Ingelheim Pharmaceuticals Inc. were slapped on Friday with another proposed class action, this one in Pennsylvania federal court, over an alleged $120 million deal to delay the entry into the market of a generic version of a stroke-prevention medication.

A health and welfare fund for the National Electrical Contractors Association and the International Brotherhood of Electrical Workers claimed in a class action complaint that a pay-for-delay agreement between Boehringer and Teva subsidiary Barr Pharmaceuticals Inc. has caused indirect purchasers of Boehringer's...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.